Validity of Serum Markers for Fibrosis Staging in Chronic Hepatitis B and C Patients Volume 3 - Issue 1

Irfan Ahmad*

• Government Medical College, Srinagar, India

Received: November 11, 2020;   Published: December 11, 2020

*Corresponding author: Irfan Ahmad, Government Medical College, Srinagar, India

DOI: 10.32474/CTGH.2020.03.000154

 

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

According to latest report globally about 350 million people are affected by Hepatitis B virus and about 686,000 die every year from Hepatitis B related diseases[1,2]. Similarly, more than 185 million people around the world are infected with Hepatitis C virus, of whom 350,000 die each year[3,4]. Hepatic fibrosis, regardless of the underlying a etiology, is a consequence of accumulation of extracellular matrix components in the liver. This process is caused by persistent liver damage and consequent wound healing reaction, leading to cirrhosis, portal hypertension, and hepatocellular carcinoma (HCC), all these cumulatively leading to increased morbidity and mortality [5,6]

Introduction| Materials and Methods| Résults| Discussion| Conclusion| References|